论文部分内容阅读
目的了解羟甲戊二酰辅酶A还原酶抑制剂氟伐他汀对慢性肾脏病(CKD)2期的胱抑素-C(Cystatin-C)影响,应用Cystatin-C来评价肾功能变化。方法选择42例慢性肾病2期患者,随机分成两组,在原有基础治疗上治疗组22例患者予以氟伐他汀治疗,对照组20例单纯以基础治疗,在24周时监测TC、TG、24h尿蛋白定量、尿素氮、Scr、Cystatin-C水平。结果与治疗前相比,治疗后两组24h尿蛋白定量、Cystatin-C均明显下降(P<0.05),治疗组血脂明显下降(P<0.05)。与对照组相比,治疗组血脂有显著下降(P<0.01),而且24h尿蛋白、Cystatin-C均明显下降(P<0.05)。结论氟伐他汀能降低CKD2期患者蛋白尿,延缓慢性肾功能不全早期的进展。
Objective To investigate the effect of fluvastatin, a inhibitor of hydroxymethylglutaryl coenzyme A reductase, on Cystatin-C in stage 2 of chronic kidney disease (CKD). Cystatin-C was used to assess renal function. Methods Twenty-two patients with chronic nephropathy were divided into two groups randomly. Twenty-two patients in the original treatment group were treated with fluvastatin, while those in the control group were treated with simple therapy. TC and TG were monitored at 24 weeks Urinary protein, urea nitrogen, Scr, Cystatin-C levels. Results Compared with those before treatment, 24 h urinary protein excretion and Cystatin-C were significantly decreased (P <0.05), and the blood lipids in the treatment group were significantly decreased (P <0.05). Compared with the control group, the blood lipids in the treatment group decreased significantly (P <0.01), and the levels of urinary protein and Cystatin-C in 24 hours decreased significantly (P <0.05). Conclusion Fluvastatin can reduce proteinuria in patients with CKD2 and delay the early progression of chronic renal failure.